

SUBJECT INDEX

A

Abasic site, 91, 93
Acetaldehyde, 25, 138
Acrylonitrile, 35, 138
Acute lymphoblastic leukaemia, 242, 247, 265
Acute myeloid leukaemia, 69, 245, 281
Acute promyelocytic leukaemia, 97, 244, 246
Adenoma sebaceum, 268
Adenomatous polyps of the small intestine, 268
Adrenocortical carcinoma, 72, 268
Aflatoxins, 34, 37, 43, 44, 46, 90, 91, 94, 102, 203- 205
AIDS, see human immunodeficiency virus
Air pollution, 39, 139, 182, 184
Alcohol cirrhosis, 146
Alcohol dehydrogenase, 30
Alcohol drinking, 22, 26, 29, 64, 135, 189, 195, 199, 203, 204, 223, 232, 236, 307, 313, 322
ALK5, 250
Alkylating agents, 49, 91, 283, 285
O⁶-Alkylguanine-DNA-alkyltransferase, 95, 285
Aluminium production, 36
4-Aminobiphenyl, 34, 94
Anabolic steroids, 204
Anal cancer, 68
Analgesics, 49, 85
Anaplastic large cell lymphoma, 239
Androgen receptor, 77, 80, 209
Androgenic (anabolic) steroids, 50
Androgens, 209
Angiofibroma, 268
Angiogenesis, 96, 122, 152, 191, 201
Angiomyolipoma, 268
Angiosarcoma, 34, 94, 204
Anthracyclines, 60, 186, 197, 206, 219, 230, 241, 245, 281, 282, 285, 286
Antibiotics, 58, 283
Anti-EGFR monoclonal antibody, 123
Anti-emetics, 286, 287
Antimetabolites, 285
Antiretroviral, 49
Aortic aneurysm, 131
APC, 72, 73, 99, 111, 112, 121, 153, 164, 196, 198, 199, 200, 201, 206, 226, 268
Apoptosis, 54, 59, 77, 79, 83, 84, 98, 100, 113-117, 121, 152, 153, 191, 213, 244, 290
Aromatic amines, 27, 35, 89, 135, 228-230
Arsenic and arsenic compounds, 25, 34, 36, 39-41, 138
Asbestos, 26, 34, 36, 37, 39, 135-137, 154, 183, 186, 229, 233, 261
L-Asparaginase, 283

Aspergillus, 44
Aspirin, 118, 152, 154, 199
Astrocytoma, 268
Ataxia telangiectasia (ATM), 68, 72, 93, 100, 114, 191, 192, 251
ATB, 251
ATM, see ataxia telangiectasia
Atmospheric pollution, see air pollution
Atomic bomb, 51, 183
Atrophic gastritis, 195
Autoimmune disease, 68
Axillary freckling, 268
Azathioprine, 49, 68

B

BAD, 117
Barrett oesophagus, 225
Basal cell carcinoma, 72
Base excision repair, 91, 93
Bax, 54, 99
BCG, 230
Bcl-2, 98, 99, 113, 115, 191, 206
Bcl-XL, 117
BCNU, 50
Behaviour, 21, 53, 141, 142, 146, 167, 215, 221, 308, 310
Benz[a]anthracene, 35
Benzal chloride, 35
Benzene, 27, 34, 36, 40, 45, 242
Benzidine, 34, 35
Benzo[a]anthracene, 25
Benzo[a]pyrene, 25, 35, 90, 94, 138
Benzo[b]fluoranthene, 25
Benzoyl chloride, 35
Beryllium, 34
Betel quid, 22, 224, 233
Bidi, 23
Bilateral acoustic neuroma, 72
Bile ducts, 35, 49
Binge drinking, 31
N,N-bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine), 49
Bis(chloroethyl)nitrosourea (BCNU), 50
Bis(chloromethyl)ether, 34, 138
Bladder cancer, 15, 22, 24, 33-37, 41, 42, 49, 57, 58, 64, 68, 75, 85, 94, 111, 131, 135, 228, 229, 284, 318
Bleomycin, 49, 214, 222, 241, 286
Bloom syndrome, 72
Bone metastases, 278
Bowel cancer, see colorectal cancer
Brachytherapy, 280
Bracken, 44

Brain cancer, see nervous system tumours
BRCA1, 71, 73-75, 99, 106, 114, 190, 191, 206, 219, 220, 250,
251, 272, 273, 322
Breakpoint cluster region, 244
Breast cancer screening, 156, 190
Breast cancer, 12, 25, 29-31, 45, 48, 49, 64, 72-79, 85, 97, 102,
105, 106, 111, 120, 151, 188, 191, 220, 251, 268, 273, 281,
282, 284, 291, 307, 322
BRMS1, 120
1, 4-Butanediol dimethane-sulfonate, 49
Bupropion, 28, 133
Burkitt lymphoma, 68, 237-240, 281
Busulfan, 49
1,3-Butadiene, 35, 136
Butylated hydroxyanisole, 85
Bystander effect, 110

C

E-Cadherin (CAD1), 111, 199, 120, 206, 219, 226
Cadmium, 34
Café-au-lait spots, 268
Cancer education in medical courses, 280
Cancer in mixed hyperplastic adenomatous polyps (MHAP), 86
Cancer registries, 14, 309, 312, 315
Cancer vaccine, 290, 291
Canthaxanthin, 152
Carbon monoxide (CO), 138
Carcinoembryogenic antigen (CEA), 191
Carcinogen activation, 89
Cardiac rhabdomyomas, 268
Carotenoids, 65, 151, 152, 194, 229
 β -Carotene, 152
Caspases, 191
 α -Catenin, 111
 β -Catenin, 111, 199, 205, 266
 γ -Catenin, 111
Cationic trypsinogen, 251
CC>TT transitions, 94
CCND1, 105
CCNU, 50
CD44, 196, 199, 219
CD95, see Fas
CDC25A, 105
CDC25B, 105
CDK (cyclin dependent kinase), 106
CDK2, 107
CDK4, 73, 105, 107
CDK6, 105, 107
CDKI (cyclin dependent kinase inhibitor), 106
CDKN2, 101, 107, 204, 255
CDKN2A (p16INK4A), 105, 186, 206, 226
Cell adhesion, 109, 120, 191, 226
Cell cycle arrest, 54, 98
Cell cycle checkpoints, 106
Cell cycle, 83, 96-98, 100, 101, 104, 114
Cell division, 83, 85, 96, 99, 104, 105, 108, 281, 282
Cell mobility, 191

Cell-cell communication, 109
Cellular phones, see mobile telephones
Centers for Disease Control and Prevention (CDC), 310
c-erbB2 (neu), 191, 196, 206, 219, 226
Cerebral astrocytoma, 72
Cerebrovascular disease, 131
Cervical cancer screening, 167, 305, 314, 316, 318
Cervical cancer, 15, 25, 49, 56-58, 60, 61, 68, 88, 101, 148, 150,
167, 172, 215, 216, 280, 284, 305, 307, 316
Chemical carcinogen, 22, 27, 43, 46, 69, 84, 89
Chemotherapeutic drugs, 283
Chemotherapy, 281, 317, 323
Chernobyl accident, 51, 257, 258
Chewing tobacco, 22, 233
Childhood malignancies, 54, 242, 265, 281
Chk1, 114
Chk2, 114
Chlorambucil, 49, 286
Chloramphenicol, 50
Chlorinated toluenes, 35
Chlorination, 39, 41
1-(2-Chloroethyl)-3-(4-Methyl-cyclohexyl)-1-nitrosourea
(Methyl CCNU), 49
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU), 50
Chlorofluorocarbons, 39, 41
Chloroform, 138
Chloromethyl methyl ether, 34
4-Chloro-*ortho*-toluidine, 35
para-Chloro-*ortho*-toluidine, 35
Cholangiocarcinoma, 57, 204, 205
Choriocarcinoma, 281, 284
ChromiumVI, 138
Chronic active gastritis, 61
Chronic active hepatitis, 44
Chronic lymphocytic leukaemia, 239, 242, 244
Chronic myelogenous leukaemia, 242, 243, 244
Chronic myeloid leukemia, 245
Chronic obstructive lung disease, 131
Chrysene, 25
Ciclosporin, 49, 68
Cigarettes, 22, see tobacco
Cirrhosis, 31, 144, 145, 203, 204, 273, 274
Cisplatin, see platinum drugs
Classification of tumours, 193
Clear cell carcinoma of the kidney, 263
Clear cell carcinoma of the vagina, 48
Clinical trials, 123, 133, 145
Clonorchis sinensis, 57, 204
CMM2, 251
Coal tar, 34, 36
Cobalt source, 278, 307, 317
Colectomy, 273
Colonoscopy, 165
Colorectal cancer screening, 163, 199
Colorectal cancer, 63-65, 72, 73, 85, 86, 94,
95, 99, 105, 111, 118-121, 124, 151, 153, 163,
196, 198, 200, 206, 268, 273, 281, 284
Complementary and alternative medicine, 299

Comprehensive Cancer Centres, 317
Connexins, 111
Cooking oil vapours, 41
Cowden syndrome, 72, 199, 268
COX-1, 152, 153
COX-2, 152, 153
Creosotes, 35
Crotonaldehyde, 25
Cryptorchidism, 273
Crystalline silica, 33, 38, 137
Cutaneous angiofibroma (adenoma sebaceum), 268
Cyclin A, 206
Cyclin D, 101, 105-108, 206, 219, 225, 230
Cyclin E, 107, 196
Cyclin-dependent kinases, 105
Cyclophosphamide, 49, 68, 69, 186, 219, 222, 229, 240, 241, 243, 282, 286, 289
CYP2E1, see Cytochrome P450
Cytarabine, 245, 282, 283, 286
Cytochrome P450 (CYP2E1), 30, 44, 90
Cytokines, 54
Cytotoxic T lymphocytes, 288

D

Daunorubicin, see anthracyclines
DCC, 85, 196, 199, 219, 267
DcR3, 287
Diabetes, 251
Dibenz[a,h]anthracene, 35
Dibenzo[a,h]anthracene, 25
Dibenzo[a,l]pyrene, 25
Dichlorobenzene, 85
1,2-Dichloroethane, 138
Diesel engine exhaust, 34, 37, 138
Diet, 62, 79, 88, 151, 154, 176, 184, 189, 194, 198, 209, 220, 233, 248, 258, 307, 313, 321
Dietary fibre, 64, 118, 153, 199, 248
Diethyl sulfate, 35
Diethylstilbestrol, 48, 49, 212, 216
Diffuse large B-cell lymphoma, 69, 239, 240
Digital rectal examination, 161
Dimethyl sulfate, 35
Dimethylcarbamoyl chloride, 35
Dimethylphosphate, 139
Dioxins, 42, 46, 69
DNA adducts, 45
DNA damage, 44, 53, 59, 71, 73, 89, 91, 93, 100, 107, 114, 115, 277, 279
DNA hypomethylation, 85, 199
DNA ligase, 93
DNA mismatch repair, 93, 94, 250
DNA repair, 54, 71, 86, 89, 96, 99, 100, 102, 107, 185, 201, 234, 277, 285
Docetaxel, see taxanes
Dose-response, 24, 68, 128, 277
Doxorubicin, see anthracyclines
DPC4, 120, 250

DR5, 99
Drug combinations, 48, 186, 217, 244, 281, 284, 285, 323
Drug resistance, 219, 247, 256, 263, 281, 282, 285
Ductal carcinoma in situ, 190
Dysplastic gangliocytoma of the cerebellum (Lhermitte-Duclos), 268
Dysplastic naevus syndrome, 254

E

E2F transcription factor, 105, 107
E6 protein, 150
E7 protein, 150
EBV, see Epstein-Barr virus
EGF, 191
EGFR, 123, 191, 225-227, 266
Electromagnetic fields, 51, 53, 243
Endometrial cancer, 48, 49, 62, 66, 73, 76, 85, 215, 218, 291
Endoscopy, 164, 195, 200, 226, 228, 274
Environmental pollution, 39, 135
Environmental tobacco smoke, 22, 25, 27, 34, 37, 41, 128, 134, 139, 182, 310
Ependymoma, 266, 268
Epichlorohydrin, 35
Epidermal growth factor (EGF), 191
Epstein-Barr virus, 56, 57, 59, 68-70, 232-234, 237, 238
ERBB2, 97, 120, 186, 220, 291
Erythroplakia, 173
Essential drugs list, 286
Estrogen derivatives, 58
Estrogen receptor, 48, 78, 153, 191, 291
Estrogen therapy, 49
Estrogens, 49, 85, 209
Ethics, 74, 221, 272, 300, 322, 324
Ethylene oxide, 34
Etoposide, 48-50, 186, 214, 222, 241, 243, 282, 283, 286
Ewing's sarcomas, 284
Excision repair, 92
Extracellular matrix, 123
Extracellular signal-regulated kinase (ERK), 117

F

FAC, 72
Faecal occult blood test, 163, 165, 200
Familial adenomatous polyposis (FAP), 72, 99, 153, 164, 200, 201, 250, 273
Familial atypical mole syndrome, 254
Familial atypical multiple mole melanoma (FAMMM), 251
Familial breast cancer, 190, 273
Familial ovarian cancer, 273
Familial pancreatic cancer, 251
Familial predisposition, 85
FAMMM, 251
Fanconi anaemia, 72
FAP, see Familial adenomatous polyposis
Fas, 54, 115, 116, 226, 287, 288
Fas Ligand (Fas-L), 54, 287, 290
FHIT, 186, 225, 226

Fibroblast growth factor (FGF), 117
Fibroma, 268
Fine particles, 39
5-Fluorouracil (5-FU), 197, 206, 251, 263, 282, 283, 285, 286
FOBT test, 165
Folic acid, 65, 281
Follicular lymphoma, 239
Food additives, 64
Food contaminants, 43, 56, 63, 204, 224
Food preparation, 43, 46
Formaldehyde, 25, 35
Framework Convention on Tobacco Control, 308
Fruit, 30, 46, 62-64, 151, 154, 175, 184, 189, 194, 198, 223, 233, 307
Fusarium, 44, 224

G

G>A transitions, 94
G>T transversions, 94
Gamma radiation, 53
Gap junctional communication, 110
Gap junctions, 109
Gastric atrophy, 61
Gastric cancer, see stomach cancer
Gastritis, 58, 60, 61, 63, 175, 176, 194, 195
Gene therapy, 111, 287, 289
Gene-environment interactions, 74, 90, 230
Genetic background, 219
Genetic instability, 96, 196
Genetic susceptibility, 71
Genomic instability, 58, 95, 107, 285
Genotoxic, 46, 84, 89, 91, 100
Germ cell tumours, 212, 213, 220, 221, 265, 267, 281
Germline mutation, 71
Gliial hamartias, 268
Glioblastoma, 266-268, 278, 281, 295
Glioma, 120
Global Strategy for Cancer Reduction, 326
Globocan 2000, 14
Glutathione transferase, 44
Gonadotrophins, 85
Gorlin syndrome, 72, 268
Granulocyte-macrophage colony-stimulating factor, 187, 289
Growth factor receptor-bound protein (GRB), 117
Growth factors, 60, 79, 97, 109, 115, 117, 122, 123, 250

H

H. pylori, see *Helicobacter pylori*
HAART therapy, 70
Haemangiosarcoma, 138, 268
Haematuria, 139
Haemochromatosis, 204
Hamartoma, 268
HBV-X protein, 44
Head and neck cancer, 25, 27, 29, 60, 232, 236, 284
Heat shock proteins, 191

Helicobacter pylori (*H. pylori*), 12, 57-59, 63, 175, 195, 196, 238, 240
Heparanase, 122
Hepatitis B virus (HBV), see hepatitis
Hepatitis C virus (HCV), see hepatitis
Hepatitis vaccination, 56, 144, 206, 307, 314, 321
Hepatitis, 12, 34, 37, 43-45, 56, 57, 59, 102, 144, 203, 204, 206, 307, 315, 321
Hepatocellular carcinoma, see liver cancer
Hepatolithiasis, 87
HER2 (neu), 250
Herceptin, 291
Hereditary nonpolyposis colorectal cancer (HNPCC), 93, 95, 200, 201, 218, 250, 251, 273
Hereditary pancreatitis, 251
Herpesvirus 8, 68
Heterocyclic amines, 43, 46
HHR23B, 92
HHV-8, see human herpes virus-8
Histone H3, 191
HIV, see human immunodeficiency virus
hMLH1, 73, 94, 199, 219, 250, 251, 268,
hMSH2, 73, 94, 199
hMSH6, 73, 94
HNPCC, 251, 273
Hodgkin disease, 68, 240, 278, 281, see also lymphoma
Hormonal therapy, 48, 222, 291
Hormone replacement therapy, 77
Hot beverages, 224
hPMS2, 94, 199
HPV, see human papillomavirus
H-RAS, 54
HTLV-1, 57, 59
Human Genome Project, 101, 287, 324
Human herpes virus-8 (HHV-8), 57-59, 68
Human immunodeficiency virus (HIV), 57, 60, 68, 70, 216, 217, 238
Human leucocyte antigen, 234
Human papillomavirus vaccination, 68, 148
Human papillomavirus, 12, 56-58, 59, 60, 68, 148-150, 167, 170, 216, 217, 233
Human T-cell lymphotropic virus, 57, 238
Hydroxyurea, 283
Hypoxia, 98, 119

I

IARC Handbooks of Cancer Prevention, 152
IARC Monographs, 33
IARC, 315
IGF-I, IGF-II, see insulin-like growth factors
IL-10, 290
Immune escape, 287
Immunodeficiency, 68
Immunosuppression, 54, 61, 68, 70, 237
Immunotherapy, 287
Imprinting, 213
Indomethacin, 152

Infection, 12, 56, 68, 70, 144-149, 167, 175, 194, 203, 215, 228, 232, 238, 243, 321
Inflammatory bowel disease, 204
Insulin-like growth factors (IGF-I, IGF-II), 79, 99, 191, 259
Integrins, 111, 121, 287
Interleukin-10 (IL-10), 290
International Agency for Research on Cancer (IARC), 315
Interval cancers, 157
Intestinal metaplasia of the stomach, 61, 195
Intraepithelial neoplasia of the pancreas, 250
Intrahepatic cholangiocarcinoma, 206
Invasiveness, 96
Iodine intake, 258
Ionizing radiation, 51, 53, 68, 93, 192, 242
Iris hamartomas, 268
Ischaemic heart disease, 131
Isochromosome 17, 266

J

Jaw cysts, 268
Juvenile polyp, 86
Juvenile polyposis syndrome, 199

K

Kaposi sarcoma, 49, 57, 58, 60, 68
KDR, 123
Kidney cancer, 22, 24, 36, 49, 72, 85, 111, 131, 138, 261, 263, 268, 284, 318
Kidney haemodialysis, 262
KIP1, 105
KISS-1, 120
Knudson's hypothesis, 71
K-RAS, 54, 85, 186, 196, 206, 219, 250
K-sam, 196

L

Laparoscopy, 274
Laryngeal cancer, 25, 26, 31, 131, 232-236, 278
Latent period, 84, 151
Leukaemia, 25, 34-36, 42, 45, 49-54, 57, 72, 79, 131, 237, 239, 240, 242, 268, 281, 284, 286, 318
Leukoplakia, 154, 172, 234
Lhermitte-Duclos disease, 268
Li-Fraumeni syndrome, 72, 73, 99, 191, 218, 250, 265, 266, 268
Linear accelerator, 278, 317
Liver cancer, 12, 15, 34, 35, 37, 43-46, 49, 50, 53, 56-58, 61, 73, 85, 94, 102, 111, 120, 131, 138, 144, 203, 204, 206, 273, 284
Liver flukes, 58, 204
Liver transplantation, 206, 274
LKB1, 72, 250, 251
Lobular carcinoma in situ, 191
Low grade diffuse astrocytoma, 266
Lung cancer, 12, 22, 34-41, 53, 60, 65, 79, 85, 91, 94, 102, 111, 120, 128, 129, 131, 133, 138, 139, 154, 182, 268, 278, 284, 286, 306

Luteinizing hormone, 77, 79, 80, 286, 291
Lycopene, 209
Lymphangioliomyomatosis, 268
Lymphoma, 35, 45, 49, 57-60, 68-70, 72, 114, 176, 194, 211, 229, 237, 239, 244, 258, 267, 274, 281, 284, 318
Lymphoplasmacytic lymphoma, 239

M

M6P/IGF2R, 206
Major histocompatibility complex, 149, 288, 289
Malaria, 68
MALT lymphoma, 239
Mammogram/mammography, 156-158, 188, 307
Mantle cell lymphoma, 239
Mastectomy, 273
Matrix metalloproteinase inhibitors, 123
Matrix metalloproteinases, 122
Mature T-cell lymphomas, 239
MDM2, 101, 114, 267
MDR1, 219, 263, 285
Meat, 46, 63, 65, 189, 198, 223, 248
Mediastinal large B-cell lymphoma, 239
Medical exposure, 51
Medical oncology, 48, 281, 318
Medullary cancer of the thyroid, 273
Medulloblastoma, 266, 268
Melamine, 85
 α -Melanocyte-stimulating hormone, 290
Melanoma, 15, 53, 72, 73, 94, 111, 120, 122, 140-143, 152, 250, 251, 253, 255, 284, 290
Melfalan, 49
MEN1, 72, 273
MEN2, 273
Meningioangiomas, 268
Meningioma, 72, 268
6-Mercaptopurine, 283, 286
Mesenchymal tumours, 68
Mesothelioma, 26, 33, 34, 36, 39, 135, 137, 139, 183, 279
MET, 196, 206, 259, 263
Metabolic activation, 27, 89
Metals, 27, 36, 40, 43
Metastasis, 79, 84, 85, 96, 119, 124, 184, 200, 206, 235, 255-257, 265, 278, 281
Methotrexate, 69, 219, 230, 245, 282, 283, 285, 286
5-Methoxypsoralen, 50
8-Methoxypsoralen, 49
7-Methylguanine, 90
O⁶-Methylguanine, 90, 94, 95
Methyl methanesulfonate, 35
4-(Methylnitrosamino)-1-(3-pyridyl)1-butanol (NNAL), 25
4-(Methylnitrosamino)-1-(3-pyridyl)1-butanone (NNK), 25
Methyl-CCNU, 49
4,4'-Methylenebis (2-chloroaniline) (MOCA), 35, 36, 139
Methylene blue chromoendoscopy, 175
Methyl methanesulfonate, 35
O⁶-Methylthymine, 90
MHAP/Serrated adenoma, 86

Microarray, 240
Micronutrients, 65, 151, 209
Microsatellite instability, 219
Microsatellites, 93
Microwaves, 52
Migration (cellular), 121
Migration (population), 194
Minimal residual disease, 246
Mining, 36, 38, 39, 184, 248
Mismatch repair, 86, 91, 94
Mitogen-activated protein kinase kinase (MEK), 117
Mitomycin C, 91
MKK4/SEK1, 120, 250
MMAC1, 120, 268
MMP, 120, 123
Mobile telephones, 53
MOCA see 4,4'-methylenebis(2-chloroaniline)
Molecular epidemiology, 45
MOPP and other combined [anticancer] chemotherapy, 49
MPNST, 268
Multicultural issues, 221, 325
Multiple basal palmar and plantar pits, 268
Multiple endocrine neoplasia, 72, 74, 259, 273
Multistage carcinogenesis, 27, 84
Mustard derivatives, 285
Mustard gas (sulfur mustard), 34
Mutation hotspot, 94
MYC, 44, 97, 114, 191, 217, 220, 225, 239, 255
Mycotoxins, 43, 102, see also Aflatoxins
Myeloma, 281
Myleran, 49
Myocardial degeneration, 131

N

Naevi, 254
Naevoid basal cell carcinoma syndrome (Gorlin), 268
Nasal tumor, 34, 36, 138
Nasopharyngeal cancer, 35, 57, 63, 232
National Cancer Control Programmes, 304, 312
Natural killer cells, 287, 288
2-Naphthylamine, 34
Necrosis, 113
Nerve gliomas, 268
Nervous system tumours, 72, 94, 265, 266, 284
Neuroblastoma, 266
Neurofibromas, 72, 268
Neurofibromatosis, 72, 268
Neutropenia, 287
NF1, 72, 266, 268
NF2, 72, 268
Nickel compounds, 25, 34, 138
Nicotine replacement therapy, 28, 132, 133
Nitric oxide, 94, 116, 195
Nitrilotriacetate, 85
Nitrogen dioxide (NO₂), 138
Nitrogen mustard, 50

Nitrogen oxide, 40
Nitrosamines, 204
N'-nitrosoanabasine (NAB), 25
N'-nitrosoornicotine (NNN), 25
Nitrosoureas, 285
nm23, 120
N-nitropyrolidine, 25
N-nitrosamines, 25
N-nitroso compounds, 27, 46, 61, 63, 266
N-nitrosodiethylamine, 25
N-nitrosodimethylamine, 25
Nodal marginal zone lymphoma, 239
Non small cell lung cancer, 186, 281
Non-familial malignant melanoma, 254
Non-Hodgkin lymphoma, 68, 70, see also lymphoma
Non-melanoma skin cancer, 54
N-RAS, 54
Nucleotide-excision repair, 91, 92

O

Obesity, 78, see also overweight
Occupational carcinogens, 33, 135
Occupational exposure, 33, 51, 52, 54, 135
Ochratoxin, 44
Oesophageal cancer, 15, 22, 24-26, 29, 30, 35, 36, 44, 62, 65, 66, 102, 111, 131, 223, 225, 278
Oligodendroglioma, 266
Oncogene, 59, 73, 86, 91, 96, 109, 114, 217
Oophorectomy, 273
Opioid analgesics, 287, 298, 319
Opisthorchis viverrini, 57, 61, 205, 204
Optic gliomas, 72
Optic nerve glioma, 266, 268
Oral cancer screening, 314
Oral cancer, 15, 22, 24, 25, 26, 29, 30, 62, 85, 131, 154, 172, 173, 232, 309
Oral contraceptives, 49, 76, 80, 85, 204, 218, 220
Orchoplexy, 273
Organ transplantation, 68
Osteosarcoma, 72, 111, 284
Ovarian cancer, 62, 71, 73, 74, 76-80, 85, 120, 190, 215, 220, 268, 273, 275, 281, 284, 286
Ovarian fibromas, 268
Overweight, 66, 76, 261, 307
Oxygen radicals, 91
Ozone, 39, 41, 139

P

p14ARF, 100, 101, 107
p15 INK4B, 106, 199
p16INK4A, 73, 75, 100, 105-107, 186, 199, 219, 225, 226, 250, 251, 255, 266, 267
p19ARF, 105
p21, 54, 99, 106, 107, 114

p27, 105, 106
p53 germline mutation, 190
p53 mutation, 44, 85, 105, 267
p53, 22, 27, 44, 54, 59, 72, 73, 91, 94, 98-105, 107, 114, 115, 120, 164, 185, 186, 191, 196, 199, 201, 204, 206, 210, 217, 219, 225, 226, 230, 248, 250, 255, 263, 265, 268, 315
Paclitaxel, see taxanes
Palliative care, 297, 308, 323
Pancreatic cancer, 13, 22, 24, 45, 72, 73, 120, 131, 248, 250, 251, 273, 281, 284
Papanicolaou smear, 88, 167, 216
Papillary thyroid carcinoma, 258
para-Chloro-ortho-toluidine, 35
Passive smoking, see environmental tobacco smoke
Patched, 54
PAX8, 259
Peau de chagrin, 268
Penicillium, 44
Peptic ulcer, 131
Perchloroethylene, 85
Peripheral vascular disease, 131
Peritoneum, 34, 124
Pesticides, 34, 35, 42, 43, 44, 45, 137, 140, 189, 238
Petroleum, 36, 40
Peutz-Jegher syndrome, 72, 199, 251
Peutz-Jeghers polyp, 86
P-glycoprotein, see MDR1
Pheochromocytoma, 72, 268
Pharmaceutical industry, 286
Pharyngeal cancer, 24, 29, 30, 34, 57, 62, 65, 131, 154, 232
Phenacetin, 48, 49
Philadelphia chromosome, 244, 245
Phosphoinositide-3-kinase (PI3K), 117
Photofluoroscopy, 176, 195
Phyto-estrogens, 78, 209
Pilocytic astrocytoma, 266
Piroxicam, 152
Pituitary tumour, 85, 278
Platelet derived growth factor (PDGF), 117, 267
Platelet derived growth factor receptor (PDGFR), 123, 267
Platinum derivatives, 285
Platinum drugs, 49, 91, 186, 197, 206, 208, 212, 214, 219, 221, 222, 263, 282, 286
Pleura, 34, 37
PMS1, 73
PMS2, 73
Poly(ADP-ribose)polymerase (PARP), 93
Polychlorinated biphenyls, 35, 42, 45, 140, 228, 248
Polycyclic aromatic hydrocarbons, 25, 27, 33, 38, 45, 46, 63, 91, 138, 139, 228, 230
Polycystic kidney disease, 262
Polymerase chain reaction, 246
Polymorphisms, 31, 66, 80, 90, 111, 185, 209, 235, 324
Polynucleotide kinase (PNK), 93
Population ageing, 320
pRb, 105, 107
Prednisolone, 286, 287
Prednisone, 286

Premalignant lesions, 73, 84, 163, 170, 172, 175, 185, 199, 216, 224
Primary (de novo) glioblastoma, 267
Procarbazine, 48, 50, 241, 282, 283, 286
Progesterone receptors, 291
Progesterone, 85, 191
Prognostic factors, 123, 124, 282
Programmed cell death, see apoptosis 84
Promoter hypermethylation, 101, 105, 186, 250
Promutagenic DNA adducts, 89
Prophylactic vaccination, 144, 148
Prostaglandins, 151, 290
Prostate cancer screening, 160
Prostate cancer, 12, 35, 62, 73, 77, 85, 105, 111, 120, 121, 154, 160, 208, 221, 278, 281, 284, 286, 291, 324
Prostate-specific antigen, 160, 208
Prostatic intraepithelial neoplasia (PIN), 210
Proteases, 226
Protein kinase B (Akt, PKB), 117
Protein kinase C (PKC), 117
Proteolysis, 191
Proto-oncogene, 84
PTCH, 72, 266, 268
PTEN, 72, 120, 210, 219, 258, 266, 268
Pulmonary heart disease, 131
Pulmonary tuberculosis, 131
Pyridyloxobutylated adducts, 90
Pyrimidine dimer, 91
Pyrrolizidine alkaloids, 44

Q

Quitting, see smoking cessation

R

Rab11, 226
Radiation, 51-55, 141, 253
Radiotherapy, 277, 317
Radon, 36, 37, 52, 184
RAS, 91, 97, 102, 114, 117, 235, 259
RB1, 44, 72, 98, 99, 104, 105, 114, 210, 230, 267
Reactive oxygen species, 86
Recombination, 71
Recombinational repair, 91
Rehabilitation, 292
Renal cell carcinoma, 72, 261, 268
Renal pelvis cancer, 85
Replication error, 86
RET, 72, 259
Retinal haemangioblastomas, 268
Retinoblastoma, 71, 72, 98, 104, 105, 265
Retinoic acid, 153, 244, 246
Retinoids, 151, 152, 154
Rho, 122
Rubber manufacture, 34, 35
Rural areas, 40

S

Saccharin, 64, 85
Salicin, 153
Salt, 63, 64, 176, 194, 233
Sarcoma, 72, 268, 281, 284
Schistosoma haematobium, 57, 58, 228, 229
Schwannoma, 268
Secondary cancers, 48
Secondary glioblastoma, 267
Selenium, 209
Seminoma, 212
Senescence, 87
Serum pepsinogen, 177
Shade, 141
Shh, 54
Sigmoidoscopy, 164
Silica, 34
Single nucleotide polymorphisms, 324
Skin cancer, 34-37, 39, 41, 49-51, 53, 68, 69, 72, 92-94, 102, 111, 141-143, 154, 255, 268
SMAD gene family, 206
SMAD2, 199
SMAD4, 199
Small cell lung cancer, 185, 186, 281
Smoke, 232
Smokeless tobacco, 23, 25, 27
Smoking cessation, 25, 28, 75, 128, 129, 132, 133, 182, 183, 310
Smoking, see tobacco smoke
Smooth muscle tumours, 68
Snuff, 22, 233
Soil pollution, 41
Solar radiation, 37
Somatic mutation, 71
Soots, 34
Spinal ependymomas, 268
Spinal tumours, 266
Spiral CT, 185
Squalamine (NHE-3 inhibitor), 123
Squamous cell carcinoma, 53, 68, 72, 141, 142, 152, 167, 182, 185, 215, 216, 223, 230, 232
Stem cell, 240, 241, 244, 286
Steroid hormones, 191
STI-571, 246, 247, 285
STK11, 250, 251
Stomach cancer, 25, 29, 36, 42, 57, 58, 61, 63-65, 85, 94, 111, 120, 131, 175, 194, 196, 238, 274, 281, 284
Subependymal giant cell astrocytoma, 268
Subungual fibroma, 268
Sulfur dioxide (SO₂), 40, 138
Sulindac, 152
Sunburn, 142, 253
Sunlight, 51, 91, 135, 141, 253
Sunscreens, 141, 152
Surgical implants, 49
Surgical oncology, 272, 314

T

T cells, 59, 149, 242, 288, 289
Talc containing asbestiform fibres, 34
Tamoxifen, 48, 49, 151, 153, 156, 192, 218, 282, 286, 291
Taxanes, 186, 282, 283, 285, 286
TCDD, 34
Telemedicine, 276
Telomerase, 108, 206
Telomere, 108
Teniposide, 50
Testicular cancer, 60, 85, 208, 273, 281, 318
Testosterone, 85
2,3,7,8-Tetrachlorodibenzo-para-dioxin (TCDD), 34
1,1,2,2-Tetrachloroethane, 138
Tetrachloroethylene, 35
Tetraphthalic acid, 85
TGF- α , 123, 191
TGF- β , 123, 191, 259, 290
TGF β R2, 250
Thioguanine, 283
Thiotepa, 49
Thymidine kinase, 111
Thyroid cancer, 51, 52, 72, 257, 268, 273, 284
Thyroidectomy, 273
TNM staging, 191, 124
Tobacco advertising, 131
Tobacco control, 128, 306-310, 313, 323
Tobacco Free Initiative, 308
Tobacco smoke, 12, 21, 37, 91, 94, 128, 134, 140, 183, 228, 233, 248, 261, 308-310, 322
Tobacco, 22, 25, 30, 39, 41, 85, 102, 128, 182, 223, 228, 233, 248, 261, 304, 308-310, 313, 321
Tobacco-specific nitrosamines, 25
Toluene, 40
Topoisomerase, 191, 283, 285
TRAIL, 290
Transforming growth factors, see TGF- α , TGF- β
Transgenic mouse models, 113, 288
Transitional cell carcinoma of the urinary tract, 48, 228
Treasulfan, 49
Trichilemmomas, 268
Trichlorobenzene, 35
Trichloroethylene, 35, 138
Trimethylpentane, 85
TSC1, 268
TSC2, 268
Tuberous sclerosis, 268
Tumour antigens, 288-290
Tumour suppressor genes, 71, 73, 84, 86, 91, 96, 98-102, 109, 121, see also p53
TUNEL assay, 116
Turcot syndrome, 268
Tyrosinaemia, 204

U

UICC, 306
Ulcerative colitis, 273

Ulcerative colitis-associated colorectal carcinoma, 86
Ultimate carcinogen, 89
Ultraviolet radiation, 34, 37, 39, 49, 51, 54, 55, 69, 92, 94, 98,
102, 115, 139, 141, 253
UPA, 226
Uracil, 85
Urocanic acid (UCA), 54
Uterine cancer, see endometrial cancer

V

Vaccine, 149
Vaginal cancer, 49
Vascular endothelial growth factor (VEGF), 123, 191, 230, 290
Vasectomy, 209
Vegetables, 30, 46, 62, 151, 153, 175, 184, 189, 194, 198, 223,
233, 258, 307
VEGF, see vascular endothelial growth factor
VHL, 72, 263, 268
Vinblastine, 286
Vinca alkaloids, 186, 214, 219, 222, 230, 241, 281-283, 285
Vincristine, 286
Vinyl chloride, 34, 35, 94, 136, 138, 204

Vitamin A, 152, 209
Vitamin D, 209
Vitamin E, 209
Vitaxin, 123
von Hippel-Lindau disease, 72, 261, 262, 265, 268

W

Water pollution, 39, 41, 140
Western lifestyle, 76, 79, 188, 307
Wilms tumour, 71, 72, 99, 261, 263, 284
Wood dust, 34, 36, 233, 238

X

Xeroderma pigmentosum, 71, 72, 92, 100, 234
X-linked proliferative disorder, 72
XLP, 72
XPB, 92
XPC, 92
XPG, 92
X-radiation, 53